Business Context and Reporting Period
This Form 8-K filing by Ginkgo Bioworks Holdings, Inc. (DNA) reports on events occurring on August 14, 2024, and August 15, 2024. The filing details the results of a Special Meeting of Shareholders held on August 14 and the subsequent Board approval of a reverse stock split ratio on August 15.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material change reported is the shareholder approval and Board implementation of a reverse stock split. Key details include:
- Shareholder Approval: On August 14, 2024, shareholders approved three proposals: (1) authorization for a reverse stock split between 1:20 and 1:40; (2) officer exculpation; and (3) charter updates to remove obsolete merger provisions.
- Split Ratio: On August 15, 2024, the Board selected a 1:40 reverse stock split ratio for Class A, Class B, and Class C common stock.
- Implementation Timeline: The Amended and Restated Certificate of Incorporation is expected to be filed on August 19, 2024, with split-adjusted trading on the NYSE commencing on August 20, 2024.
- Warrant Adjustments: Warrant exercise prices and share quantities will be adjusted proportionally. The new exercise price is $460.00 per share (or $11.50 per warrant), requiring 40 warrants to exercise for one share of Class A common stock.
- Fractional Shares: No fractional shares will be issued; shareholders entitled to fractional shares will receive cash payments in lieu thereof.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational details of the stock split. The primary contingency noted is the requirement for a minimum of 40 warrants to be exercised to receive any entitlement due to the elimination of fractional shares upon warrant exercise.
Investor Verification Checklist
- Verify the effective date of the 1:40 reverse stock split and the commencement of split-adjusted trading on August 20, 2024.
- Confirm the new CUSIP number for Class A common stock (37611X209).
- Review the adjusted warrant terms, specifically the new exercise price of $460.00 and the requirement to exercise in blocks of 40.
- Check brokerage account statements for the treatment of fractional shares (cash payment in lieu of issuance).
- Monitor the filing of the Amended and Restated Certificate of Incorporation on August 19, 2024.